2. Academic Validation
  3. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners

Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners

  • Bioorg Med Chem. 2010 Mar 15;18(6):2178-2194. doi: 10.1016/j.bmc.2010.01.073.
Junwon Lee 1,  Sung-Han Lee 1,  Hee Jeong Seo 1,  Eun-Jung Son 1,  Suk Ho Lee 1,  Myung Eun Jung 1,  MinWoo Lee 1,  Ho-Kyun Han 1,  Jeongmin Kim 1,  Jahyo Kang 2,  Jinhwa Lee 1
Affiliations

Affiliations

  • 1 Central Research Laboratories, Green Cross Corporation, 303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi-Do 446-770, Republic of Korea.
  • 2 Department of Chemistry, Sogang University, 1 Shinsu-Dong, Mapo-Gu, Seoul 121-742, Republic of Korea.
PMID: 20181486 DOI: 10.1016/j.bmc.2010.01.073
Abstract

Novel C-aryl glucoside SGLT2 inhibitors containing 1,3,4-thiadiazole moieties were designed and synthesized. Among the compounds tested, biaryl-type compounds containing pyrazine 59, 2-furan 61, and 3-thiophene 71 showed the best in vitro inhibitory activities to date (IC(50) = 3.51-7.03 nM) against SGLT2. A selected compound 61, demonstrated reasonable blood glucose-lowering effects, indicating that the information obtained from the SAR studies in this 1,3,4-thiadiazolylmethylphenyl glucoside series might help to design more active SGLT2 inhibitors that are structurally related.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z